Multiplexing Detection Kits in Development
Dec 19 2008
The new bead-based multiplexed assays will give pharma and biotech researchers a direct comparative measurement of multiple protein expression patterns without the need for extrapolation among results from independent assays. This new powerful capability will allow
researchers to obtain an overall picture of the way a particular stimulus, such as a new drug candidate, affects multiple proteins simultaneously. Consequently a more accurate prediction of the
overall physiological effects of the stimulus, such as the response to a drug candidate, is achievable.
In addition, the new multiplexed assays will also help researchers identify differences in proteins or protein levels between healthy and disease states, providing insight into disease cause and progression.
Based on innovative fluorescence technology, the new bead-based offer higher sensitivity and a greater linear range of detection than assays that employ enzymatic or colorimetric readouts. The first bead-based kits to hit the market will target cytokines and chemokines. They will be sold as individual kits. In addition, Guava Technologies will offer several pre-packaged multiplex kits. The kits will be compatible with GuavaÂ® Flow Cytometers, such as the Guava EasyCyteâ¢ Plus System,
running GuavaÂ® Simplicity Software, which, like the detection kits, is in the final development stage and will be available within several months.
Buyers Guide - Major producers of analytical equipment who wish to introduce and sell their products to buyers in science and industry - Over 1,000 products and services that these companys man...
View all digital editions
Jan 17 2024 Birmingham, UK
Jan 24 2024 Tokyo, Japan
Jan 29 2024 Dubai, UAE
Jan 31 2024 Tokyo, Japan
Feb 03 2024 Boston, MA, USA